FOLH1 and posterior cortical atrophy: Due to its selective overexpression in 90–100% of primary PCa lesions, malignant lymph nodes, and bone metastases [8–10], PSMA is considered a reliable tissue marker for PCa and an ideal target for theranostic applications [11–15].